We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Novo Nordisk (NVO) Stock Drops Despite Market Gains: Important Facts to Note
Read MoreHide Full Article
Novo Nordisk (NVO - Free Report) closed the most recent trading day at $87.37, moving -1.51% from the previous trading session. The stock's performance was behind the S&P 500's daily gain of 1.1%. At the same time, the Dow added 0.91%, and the tech-heavy Nasdaq gained 1.35%.
The the stock of drugmaker has fallen by 15.16% in the past month, lagging the Medical sector's loss of 3.78% and the S&P 500's gain of 0.22%.
The upcoming earnings release of Novo Nordisk will be of great interest to investors. The company is predicted to post an EPS of $0.88, indicating a 23.94% growth compared to the equivalent quarter last year. Simultaneously, our latest consensus estimate expects the revenue to be $11.67 billion, showing a 22.7% escalation compared to the year-ago quarter.
For the annual period, the Zacks Consensus Estimates anticipate earnings of $3.23 per share and a revenue of $40.62 billion, signifying shifts of +19.63% and +20.49%, respectively, from the last year.
Investors should also take note of any recent adjustments to analyst estimates for Novo Nordisk. These revisions help to show the ever-changing nature of near-term business trends. As a result, upbeat changes in estimates indicate analysts' favorable outlook on the company's business health and profitability.
Our research reveals that these estimate alterations are directly linked with the stock price performance in the near future. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 0.21% higher. Novo Nordisk is holding a Zacks Rank of #3 (Hold) right now.
In terms of valuation, Novo Nordisk is currently trading at a Forward P/E ratio of 27.46. Its industry sports an average Forward P/E of 13.85, so one might conclude that Novo Nordisk is trading at a premium comparatively.
We can also see that NVO currently has a PEG ratio of 1.14. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. NVO's industry had an average PEG ratio of 1.46 as of yesterday's close.
The Large Cap Pharmaceuticals industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 140, which puts it in the bottom 45% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Remember to apply Zacks.com to follow these and more stock-moving metrics during the upcoming trading sessions.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Novo Nordisk (NVO) Stock Drops Despite Market Gains: Important Facts to Note
Novo Nordisk (NVO - Free Report) closed the most recent trading day at $87.37, moving -1.51% from the previous trading session. The stock's performance was behind the S&P 500's daily gain of 1.1%. At the same time, the Dow added 0.91%, and the tech-heavy Nasdaq gained 1.35%.
The the stock of drugmaker has fallen by 15.16% in the past month, lagging the Medical sector's loss of 3.78% and the S&P 500's gain of 0.22%.
The upcoming earnings release of Novo Nordisk will be of great interest to investors. The company is predicted to post an EPS of $0.88, indicating a 23.94% growth compared to the equivalent quarter last year. Simultaneously, our latest consensus estimate expects the revenue to be $11.67 billion, showing a 22.7% escalation compared to the year-ago quarter.
For the annual period, the Zacks Consensus Estimates anticipate earnings of $3.23 per share and a revenue of $40.62 billion, signifying shifts of +19.63% and +20.49%, respectively, from the last year.
Investors should also take note of any recent adjustments to analyst estimates for Novo Nordisk. These revisions help to show the ever-changing nature of near-term business trends. As a result, upbeat changes in estimates indicate analysts' favorable outlook on the company's business health and profitability.
Our research reveals that these estimate alterations are directly linked with the stock price performance in the near future. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 0.21% higher. Novo Nordisk is holding a Zacks Rank of #3 (Hold) right now.
In terms of valuation, Novo Nordisk is currently trading at a Forward P/E ratio of 27.46. Its industry sports an average Forward P/E of 13.85, so one might conclude that Novo Nordisk is trading at a premium comparatively.
We can also see that NVO currently has a PEG ratio of 1.14. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. NVO's industry had an average PEG ratio of 1.46 as of yesterday's close.
The Large Cap Pharmaceuticals industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 140, which puts it in the bottom 45% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Remember to apply Zacks.com to follow these and more stock-moving metrics during the upcoming trading sessions.